ANDA 219258, held by Granules India. Lisdexamfetamine Dimesylate.
As of Nov 21, 2026, ANDA 219258 (Lisdexamfetamine Dimesylate), held by Granules India, was first approved by FDA on Dec 16, 2024, with 2 approved supplements and 0 published complete response letters.
Lisdexamfetamine dimesylate chewable tablets are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 16, 2024 | Original application | Approved | None posted |
| Lisdexamfetamine Dimesylate10MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate20MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate30MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate40MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate50MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate60MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Sep 24, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 24, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 16, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters